tbuckley/cabot-search huggingface dataset:
ANEMIA OF PREGNANCY
Journal: JAMA (1929)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ARV-330: Androgen receptor PROTAC degrader for prostate cancer.
Authors: Taavi K Neklesa, Meizhong Jin, Andrew P Crew, AnnMarie K Rossi, Ryan R Willard, Hanqing Dong, Kam Siu, Jing Wang, Deborah A Gordon, Xin Chen, Caterina Ferraro, Craig M Crews, Kevin Coleman, James D. Winkler
Journal: Journal of Clinical Oncology (2016)

267 Background: The transition from localized prostate cancer to metastatic disease often involves modulation of the Androgen Receptor (AR). During the disease progression, patients progressing on enzalutamide or abiraterone therapy exhibit amplified AR, increased intra-tumoral androgen production or AR mutations leading to promiscuity to other ligands. Therefore, AR is still the principal driver of the disease. Methods: A novel approach to block AR signaling is to specifically target AR for degradation. To this end, we have developed the PROteolysis TArgeting Chimera (PROTAC) technology that employs hetero-bifunctional small molecules that simultaneously bind VHL E3 ubiquitin ligase and a target of interest (e.g. AR). Due to induced proximity between VHL and AR, an AR PROTAC leads to ubiquitination and subsequent degradation of AR. Results: Our lead AR PROTAC, ARV-330, degrades 92-98% of total AR in all cell lines tested, with 50% degradation concentrations (DC 50 ) &lt; 1nM. AR degradation suppresses the AR-target gene PSA expression, inhibits proliferation, and induces potent apoptosis in VCaP cells with maximal apoptosis observed at 20 nM. While enzalutamide loses its activity in the presence of &gt; 0.5 nM R1881, ARV-330 maintains its activity. In cells containing the AR F876L mutation, enzalutamide is an agonist; however, ARV-330 remains effective. In fact, ARV-330 is able to degrade all clinically relevant AR mutations. ARV-330 exhibits good pharmacokinetic properties, with t 1/2 values of several hours and bioavailability of &gt; 80% after sc injection. Treatment of mice with ARV-330, at doses ranging from 0.3 to 10 mg/kg, results in reduction of AR protein levels. The in vitro potency translates into in vivo efficacy, as ARV-330 demonstrates prostate involution in intact mice. In castrated mice implanted with VCaP tumors, ARV-330 shows robust reduction of plasma PSA and blockade of tumor growth. Conclusions: In summary, the AR PROTAC ARV-330 removes AR from prostate cancer cells in a potent manner and produces therapeutic effects as a result. This cellular efficacy has translated into biomarker activity and efficacy in animal models, and ARV-330 is now in preclinical development.
Leads from the MMWR. Recommendation of the Immunization Practices Advisory Committee supplementary statement of contraindications to receipt of pertussis vaccine
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A feasibility study of gefitinib in association with capecitabine (CAP) and oxaliplatin (OXA) as first-line treatment in patients with advanced colorectal cancer (ACRC)
Authors: M. Zeuli, A. Gelibter, C. Nardoni, T. Gamucci, A. Gabriele, C. F. Pollera, F. Di Costanzo, C. Signorelli, V. Ferraresi, F. Cognetti
Journal: Journal of Clinical Oncology (2004)

3748
A Final Analysis of a Phase 2, Single-Arm Study of Platelet (Plt) Responses and Remission Rates in Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim
Authors: Adrian Newland, Bertrand Godeau, Victor Priego, Jean-Francois Viallard, Maria Fernanda Lopez Fernandez, Amelia Orejudos, Angela Lopez
Journal: Blood (2014)
Abstract 3057: miR-211 is contributive to the progression of oral carcinoma through modulating transcription factor 12 (Tcf12).
Authors: Yi-Fen Chen, Shu-Chun Lin, Kuo-Wei Chang
Journal: Cancer Research (2013)

Abstract Oral squamous cell carcinoma (OSCC) is one of the prevalent neoplasms worldwide. MicroRNAs (miRNAs) are short RNA molecules that regulate pathogenesis, including OSCC carcinogenesis, by post-transcriptional down-regulation of target genes. Our previous study has identified a relationship between high miR-211 expression and the invasiveness of OSCC. This study further dissects the molecular mechanisms underlying the progression of OSCC as affected by miR-211. miR-211 is predicted to target the 3’UTR of transcription factor 12 (Tcf12). Reporter assays confirmed the direct targeting of miR-211 on Tcf12. Tcf12 is a helix-loop-helix transcription factor with obscure functions in malignancies. miR-211 expression decreased both endogenous and exogenous Tcf12. Exogenous Tcf12 expression suppressed oncogenic phenotypes of OECM-1 OSCC cells. On the contrary, knockdown of endogenous Tcf12 expression enhanced the oncogenic phenotypes of OSCC cells. Tcf12 expression was highly associated with EZH2 activity, and the expression levels of HOX family members in OSCC cells. To elucidate the in vivo oncogenic roles of miR-211 in OSCC carcinogenesis, K14 promoter driven miR-211 transgenic mouse lines (K14-GFP- miR-211) were established. The increased miR-211 expression was found to be associated with Tcf12 down-regulation in the squamous epithelium of transgenic mice. After tumor induction by 4-nitroquinoline 1-oxide, the transgenic mice exhibited more and bigger tumors comparing to wild type mice. The incidence of epithelial dysplasia on the tongue was also higher in the transgenic mice than that in control mice. In summary, this study reveals that miR-211 is a regulator of OSCC progression by targeting Tcf12. The in vivo model based on the K14-GFP-miR-211 transgenic mice will help further studies of the pathogenic mechanisms underlying OSCC progression and development of therapeutic strategy. Citation Format: Yi-Fen Chen, Shu-Chun Lin, Kuo-Wei Chang. miR-211 is contributive to the progression of oral carcinoma through modulating transcription factor 12 (Tcf12). [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3057. doi:10.1158/1538-7445.AM2013-3057
Question everything
Authors: Riccardo Pellegrino, Vito Brusasco, Martin R. Miller
Journal: European Respiratory Journal (2014)

A large study concludes that FEF25-75% and FEF75% do not provide a clinical advantage over FEV1 and FEV1/FVC http://ow.ly/tnB7DAdvances through scientific endeavour have delivered many benefits to the human race and overall these benefits have outweighed any associated problems.Not uncommonly apparent improvements in our knowledge are eventually shown to be incorrect or misguided in the light of subsequent knowledge.This might arise because a different perspective was taken on a problem so that a new understanding was achieved or it might arise because technological advances revealed imperfections in previous studies.
The IL-6R α chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo
Authors: Aysefa Doganci, Tatjana Eigenbrod, Norbert Krug, George T. De Sanctis, Michael Hausding, Veit J. Erpenbeck, El-Bdaoui Haddad, Edgar Schmitt, Tobias Bopp, Karl-J. Kallen, Udo Herz, Steffen Schmitt, Cornelia Luft, Olaf Hecht, Jens M. Hohlfeld, Hiroaki Ito, Norihiro Nishimoto, Kazuyuki Yoshizaki, Tadamitsu Kishimoto, Stefan Rose-John, Harald Renz, Markus F. Neurath, Peter R. Galle, Susetta Finotto
Journal: Journal of Clinical Investigation (2005)

Due to an error in manuscript preparation, an incorrect shRNA sequence for IRS2 was published.The correct hairpin sequence is a 19-nt stretch beginning from nt 703 of the published IRS2 cDNA sequence (XM_357863).The oligonucleotides cloned into the U6 construct for the IRS2U6 adenovirus are as follows: tcgagGTGACGCTGCAGCTTATGAttcaagagaTCATAAGCTGCAGCGTCACttttt (forward) and ctagAAAAAGTGACGCTGCAGCTTATGAtctcttgaaTCATAAGCTGCAGCGTCACc (reverse).In addition, the shRNA cassettes were cloned into the adenoviral cosmid pAxcwit, which lacks a promoter, and not the cosmid pAxCAwtit, as published..
Abstract 3286: Prediction for Long-term Effect Of Cardiac Resynchronization Therapy: Comparison Between Tissue Doppler Imaging And Speckle Tracking Imaging
Authors: Azusa Furugen, Naoki Matsuda, Kyomi Ashihara, Asako Mochida, Morio Shoda, Naoko Ishizuka, Nobuhisa Hagiwara, Hiroshi Kasanuki
Journal: Circulation (2007)

Recent studies have demonstrated that the septal-to-posterior motion delay (SPWMD) assessed by M-mode echo and the longitudinal intra-LV dyssynchrony assessed by tissue Doppler imaging (TDI) can predict chronic effects of cardiac resynchronization therapy (CRT). A newly developed 2D speckle tracking imaging (STI) has enabled assessment of not only longitudinal but circumferential regional strain of LV. We investigated the usefulness of STI in selecting patients for CRT. Methods: Fifty-one patients with heart failure symptoms and QRS duration&gt;120 ms underwent standard echocardiography, TDI and STI before CRT. Time to peak systolic velocity was measured in 12 basal and mid LV segments in apical views by TDI. The time difference between the basal septal and the basal lateral segments was calculated (TDI-SLPVD).The standard deviation of those among 12 segments was calculated (TDI-SD). Time to peak circumferential strain, radial strain and longitudinal strain were measured in basal segments in parasternal short axis and apical views by STI. The time difference between the septal and the lateral segments was calculated (CS-SL, RS-SL and LS-SL). A responder to CRT was defined as a patient whose NYHA class improved by &gt;1 class and whose LVESV reduced by &gt;10% at 6 months after CRT. Results: Thirty-six patients (71%) responded to CRT. CS-SL showed high sensitivity and specificity for predicting the responders at a cut-off point of 124 ms (Table ). The area under the ROC curve (AUC) of CS-SL was larger than that of QRS duration, SPWMD, TDI-SLPVD, TDI-SD, RS-SL and LS-SL. Conclusion: Assessment of circumferential dyssynchrony using STI seems useful in selecting patients for CRT.
AUTHOR'S REPLY
Authors: A. Bush
Journal: Thorax (1991)

An undesirable sensory attribute (“floral taint”) has been detected in red wines in North America, caused by leaves and petioles (materials other than grapes [MOG]) introduced during mechanical harvest after killing frosts. From 2017 to 2019, several harvest strategies were evaluated on Ontario Cabernet franc: hand harvest (HH), conventional machine harvesting (MECH), Braud-New Holland Opti (OPTI), Gregoire GL8, MECH + optical sorting (MECH+OS), and MECH with preharvest leaf removal (MECH+BLR). Concentrations of 41 odor-active compounds were quantified by gas chromatography-mass spectrometry. Harvest treatment effects varied by season. In 2017, HH resulted in lowest ethyl isobutyrate (MECH+BLR), ethyl nonoate, cis-linalool oxide (plus MECH and OPTI), trans-linalool oxide (plus MECH+OS), β-citral, and cis- and trans-rose oxide (plus MECH and OPTI). Ethyl hexanoate was lowest in MECH, and MECH+BLR, isoamyl hexanoate was lowest in all treatments except HH, and α-ionone was lowest in MECH and MECH+BLR. In 2018, HH resulted in the lowest β-damascenone, ethyl salicylate (plus OPTI and Gregoire), citronellol (plus Gregoire), cis- and trans-rose oxide (plus Gregoire), and eugenol (plus Gregoire). Isobutyl acetate, isoamyl hexanoate, and nerol were additionally reduced by Gregoire, and isopropylmethoxypyrazine was reduced by all treatments except HH. In 2019, harvest strategy affected 27 of 41 compounds, including 11 esters and 12 terpenes. Treatments leading to lowest concentrations were HH (nine compounds), MECH (eight compounds), MECH+BLR (10 compounds), OPTI (21 compounds), Gregoire (10 compounds), and MECH+OS (22 compounds). Wines from fruit that had undergone a killing frost contained different concentrations of 14 and eight compounds (2018), and 17 and 13 compounds (2019) for Cabernet franc and Cabernet Sauvignon, respectively. Results suggest that specific harvest technologies can reduce MOG and associated increases in aroma compounds, although seasonal differences may occur.
Gray-scale ultrasonography of the neck
Authors: G. A. Gooding
Journal: JAMA (1980)

ULTRASONOGRAPHY of the neck is a valuable tool not only in the diagnosis of diseases of the thyroid, parathyroid, and major salivary glands, but also in the characterization of cervical masses and in the delineation of vascular structures in this relatively superficial anatomical area. Since depth penetration is not needed, high-resolution 5-MHz 6-mm transducers produce the sharpest images for direct-contact B-mode gray-scale ultrasonography of the neck. Gray-scale sonographic units using a water bath are also commercially available, as is an automated sector scanner that uses water-delay technology. The most advanced real-time sonographic units for the neck have a 10-MHz transducer for improved resolving power.<sup>1</sup> Because the vast majority of masses in the neck are palpable, a manual examination of the neck precedes ultrasonography and defines the area in question. For anterior and lateral lesions of the neck, the patient lies supine, with the neck hyperextended by a sponge. Posteriorly
COFFEY-HUMBER TREATMENT FOR CANCER
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OUR SOUVENIR NUMBER.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Contents: (Adv. Healthcare Mater. 1/2014)
Journal: Advanced Healthcare Materials (2014)

Moving Healthcare ForwardSilicon quantum dots can be used as in vitro and in vivo imaging agents and carriers for drug delivery because of their wide fl uorescence spectral regions from near-infrared to near-ultraviolet ranges and biocompatible property.This Review introduces the synthesis, surface functionalization, optical property, and biological application of silicon quantum dots.
Local News
Authors: Frederick Foote
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Myer Tobias
Authors: O. Dover
Journal: BMJ (2009)

<h3>Abstract</h3> Generation of hierarchical structures, such as the embedding of subordinate elements into larger structures, is a core feature of human cognition. <i>Discrimination</i> of well-formed hierarchies is thought to rely on lateral prefrontal cortex (PFC). However, the brain bases underlying the <i>active generation</i> of new hierarchical levels remain poorly understood. Here, we created a new motor paradigm to isolate this <i>active</i> generative process. In fMRI, participants planned and performed (identical) movement sequences based on three previously learned rules: (1) a hierarchical ‘fractal’ rule that involved generation of new levels, (2) a linear ‘iterative’ rule adding items to existing hierarchical levels, and (3) simple ‘repetition’. We found that generation of new hierarchical levels (using the fractal rule) activated a bilateral motor planning-and imagery network, but did not involve lateral PFC. Conversely, adding items to existing hierarchical levels required M1 directly during execution. These results show that the generation of new hierarchical levels can be achieved without involvement of putative domain-general systems such as those ascribed to lateral PFC. We hypothesize that these systems might be important to <i>parse</i> hierarchical sequences in a multi-domain fashion but not necessarily to <i>generate</i> new hierarchical levels.
MEDICAL CONFIDENCES AND PROFESSIONAL HONOR.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM)
Authors: Lionel Ades, Thomas Prebet, Aspasia Stamatoullas, Christian Recher, Romain Guieze, Emmanuel Raffoux, Krimo Bouabdallah, Mathilde Hunault, Eric Wattel, Laure Stalnikiewicz, Andrea Toma, Herve Dombret, Norbert Vey, Claude Gardin, Benedicte Samey, Sylvie Chevret, Pierre Fenaux
Journal: Blood (2013)